Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:38 PM
Ignite Modification Date:
2025-12-24 @ 5:38 PM
NCT ID:
NCT02400268
Eligibility Criteria:
Inclusion criteria:
* Adults patients (equal or over 18 years old)
* Primary or secondary bloodstream infection produced by enterobacteriaceae
* Source of bacteremia properly controlled or expect to be properly controlled in the next 24 hours (i.e. bacteremia produced by infected vascular catheter, abscess, obstruction of the biliary or urinary tract).
* Patients able to understand the objectives of the clinical trial and informed consent signed.
Exclusion Criteria:
* Pregnancy
* Post-chemotherapy neutropenia expected to persist more than 7 days.
* Source of bacteremia uncontrolled at inclusion period or in the following 24 hours. The source will be considered as uncontrolled if the bacteremia is secondary to a suppurative infection potentially removable, if no action has been taken to eradicate it, including: bacteremia by vascular not removed catheter, cholangitis secondary to not derived obstruction of the biliary tract, deep abscess not drained, pyohydronephrosis without derivation of the urinary tract.
* Bacteremia secondary to infective endocarditis, bone and joint infections, or neurosurgical infections, which may require prolonged antimicrobial therapy
* Bacteremia due to enterobacteriaceae resistant to carbapenemics.
* Polymicrobial bacteremia including microorganisms different to enterobacteriaceae.
* Patients with no expectations of survival in the next 48 hours of inclusion.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02400268
Study Brief:
Protocol Section:
NCT02400268